RCI002 / RudaCure - LARVOL DELTA

Rci002, a novel trpv1 peptide antagonist, potently alleviates neuropathic pain without hyperthermia (Neuroscience 2025) - "This novel mechanism enables significant analgesia without hyperthermic side effects. These results suggest that RCI002 offers a promising new therapeutic strategy for neuropathic pain, combining high efficacy with an improved safety profile as a peptide TRPV1 antagonist."

CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain • TRPV1

The Analgesic Effect of RC-0165, a TRPV1 Antagonist, for Osteoarthritis Pain (ACR Convergence 2023) - "In vivo, pain-related behavioral effects were compared to RC-0165 and triamcinolone acetonide (TA)as positive control in a MIA-induced OA rat model, which was assessed using Von Frey, Hargreaves, open field, and rotarod tests. The results of our study suggest that RC-0165 may be a promising approach to significantly reduce OA pain compared to TA by suppressing pain signals mediated by TRPV1 effects of RCI002 compare to TA for OA"

Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • TRPV1

The antinociceptive effects of selective TRPV1 antagonist RCI002 against chemotherapy-induced peripheral neuropathy. (ASCO 2023) - "TRP vanilloid 1 (TRPV1) may contribute to the development of mechanical allodynia and thermal hyperalgesia after cisplatin or oxaliplatin treatment. Our findings suggest that RCI002 may be a promising approach to reduce paclitaxel-induced hyperexcitability and thereby to reduce neuropathy pain."

Immunology • Neuralgia • Oncology • Pain • Peripheral Neuropathic Pain • TRPV1